CRISPR THERAPEUTICS AG Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
CRISPR THERAPEUTICS AG (CRSP) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $80.30 million as of 2023-12-31, per its 10-K filed 2024-02-21.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2024-02-21
- 2023-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $80.30M.
- 2023-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $85.90M.
- 2023-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $101.70M.
- 2023-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $117.40M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2023-12-31 | $80.30M 10-K · filed 2024-02-21 |
| 2023-09-30 | $85.90M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $101.70M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $117.40M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $107.90M 10-K · filed 2023-02-21 |
| 2022-09-30 | $121.40M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $142.70M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $157.60M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $150.60M 10-K · filed 2022-02-15 |
| 2021-09-30 | $159.20M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $183.60M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $191.30M 10-Q · filed 2021-04-27 |
| 2020-12-31 | $132.50M 10-K · filed 2021-02-16 |
| 2020-09-30 | $105.50M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $205.80M 10-Q · filed 2020-07-27 |
| 2020-03-31 | $107.30M 10-Q · filed 2020-04-28 |
| 2019-12-31 | $96.20M 10-K · filed 2020-02-12 |
| 2019-09-30 | $93.30M 10-Q · filed 2019-10-28 |
| 2019-06-30 | $104.30M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $107.60M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $83.30M 10-K · filed 2019-02-25 |
| 2018-09-30 | $90.60M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $90.40M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $74.60M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $42.20M 10-K · filed 2018-03-08 |
| 2017-09-30 | $37.00M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $35.70M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $28.90M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $23.40M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |